Come together

Aelin Therapeutics N.V. is developing first-in-class synthetic peptides that could treat antibiotic-resistant Gram-negative infections by inducing toxic protein aggregation within bacterial cells.

By harnessing a novel mechanism of action that disrupts proteostasis, Aelin could circumvent growing resistance to existing antibiotics, which typically act by disrupting the bacterial cell membrane. ...